APRAMYCIN manufacturers
- Apramycin
-
- $0.00 / 1kg
-
2025-06-19
- CAS:
- Min. Order: 50kg
- Purity: 99%
- Supply Ability: 1000kg
- Apramycin
-
- $15.00 / 1KG
-
2021-07-13
- CAS:37321-09-8
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
- Apramycin
-
- $15.00 / 1KG
-
2021-07-09
- CAS:37321-09-8
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
| | APRAMYCIN Basic information |
| Product Name: | APRAMYCIN | | Synonyms: | APRAMYCIN;3,7-trideoxy-7-(methylamino)-d-glycero-alpha-d-allo-octadialdo-1,5:8,4-dipyra;ambylan;C01555;ApryMycin;O-4-Amino-4-deoxy-alpha-D-glucopyranosyl-(1-8)-O-(8R)-2-amino-2,3,7-trideoxy-7-(methylamino)-D-glycero-alpha-D-allo-octodialdo-1,5:8,4-dipyranosyl-(1-4)-2-deoxy-D-streptamine;Apramycin
(Nebramycin II);CS-1309 | | CAS: | 37321-09-8 | | MF: | C21H41N5O11 | | MW: | 539.58 | | EINECS: | 253-460-1 | | Product Categories: | Peptide Synthesis/Antibiotics | | Mol File: | 37321-09-8.mol |  |
| | APRAMYCIN Chemical Properties |
| Boiling point | 823.0±65.0 °C(Predicted) | | density | 1.56 | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 12.91±0.70(Predicted) | | color | Crystals | | Major Application | (Pharmaceutical small molecule) | | InChIKey | WGLYHYWDYPSNPF-RQFIXDHTSA-N | | EPA Substance Registry System | Apramycin (37321-09-8) |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | APRAMYCIN Usage And Synthesis |
| Chemical Properties | Crystals. Sol in water;
sltly sol in lower alcs. | | Uses | Antibacterial. | | Uses | Apramycin is used in treatment and prevention of nephrotoxin-induced kidney injuries. | | Definition | ChEBI: An aminoglycoside that is 2-deoxystreptamine that is substituted on the oxygen at position 4 by an (8R)-2-amino-8-O-(4-amino-4-deoxy-alpha-D-glucopyranosyl)-2,3,7-trideoxy-7-(methylamino
-D-glycero-alpha-D-allo-octodialdo-1,5:8,4-dipyranos-1-yl) group. | | Safety Profile | When heated to decomposition itemits acrid smoke and irritating fumes. | | in vivo | Apramycin (200 mg/kg/d, s.c., 9 d) demonstrates significant in vivo efficacy in lungs of M. tuberculosis low-dose aerosol infection model IFN-γ knockout mice[2].
Apramycin (16, 32, 80 mg/kg, s.c., 24 h) dose-dependently reduces bacterial burden in the kidneys between 2-5 log10 and in blood between 2-3 log10 for neutropenic model of Staphylococcus aureus septicemia mice[2].
Apramycin (50 mg/kg/d, s.c., 21 d) induces nephrotoxicity scores comparable to those induced by Gentamicin (10 mg/kg/d)[3].
| Animal Model: | M. tuberculosis low-dose aerosol infection model of IFN-γ knockout mice [2] | | Dosage: | 200 mg/kg/d | | Administration: | Subcutaneousinjection (s.c.) for 9 d | | Result: | Showed a 2.4-log10 CFU reduction and better antituberculous activity compared to Amikacin (1.8-log10 reduction). |
|
| | APRAMYCIN Preparation Products And Raw materials |
|